The first reports of IgA anti-B2GPI’s potential role in APS diagnosis emerged in the late 1990s from case reports of patients with APS and IgA anti-B2GPI with an otherwise negative aPL profile and also from relatively small patient cohort studies demonstrating an association between IgA anti-B2GPI and APS manifestations [21,25,26,27]. The gene discussed is APOH; the disease is autoimmune polyendocrinopathy.